A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination With Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients With Relapsed or Refractory (R/R) Esophageal Cancer (EC) or Gastro-esophageal Junction (GEJ) Tumors; Part B: An Expansion Cohort in Patients With R/R EC or GEJ Tumors; Part C: An Expansion Cohort in Patients With R/R Esophageal or GEJ Adenocarcinoma; Part D: An Expansion Cohort in Patients With R/R Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients With R/R Gastric Adenocarcinoma With Wnt Signaling Alterations

Trial Profile

A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination With Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients With Relapsed or Refractory (R/R) Esophageal Cancer (EC) or Gastro-esophageal Junction (GEJ) Tumors; Part B: An Expansion Cohort in Patients With R/R EC or GEJ Tumors; Part C: An Expansion Cohort in Patients With R/R Esophageal or GEJ Adenocarcinoma; Part D: An Expansion Cohort in Patients With R/R Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients With R/R Gastric Adenocarcinoma With Wnt Signaling Alterations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs DKN 01 (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics
  • Most Recent Events

    • 12 Sep 2017 Results (n=34) of prospective plasma biomarker analysis, presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Aug 2017 According to a Leap Therapeutics media release, first patient has been enrolled in the new arm of DKN-01 esophagogastric cancer focused on genetically defined Wnt pathway mutations in this trial.
    • 03 Apr 2017 Results from this trial were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, according to a Leap Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top